SGHT Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2020βFY2025
Sight Sciences, Inc. had $77.4M of revenue in fiscal 2025, down 3.1% on the year before. Over five years, revenue changed +22.9% a year on average.
Last close Β· Oct 26, 2026
$9.02
+$3.74 (+70.83%) past year
Hi! I read Sight Sciences, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β3.1%
No. Sales fell 3.1% last year.
Does it make a profit?
β49.7%
No. It lost money last year.
Does profit turn into cash?
β38.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA summarises the numbers
Sight Sciences, Inc. had $77.4M of revenue in fiscal 2025, down 3.1% on the year before.
Over five years, revenue changed +22.9% a year on average.
Its operating margin was β48.0%, up 15.3Β pts: of every 100 in sales, about β48 is left after running the business.
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Loss periods are shown in red.
KIRA summarises the numbers
Sight Sciences, Inc. lost $38.4M in fiscal 2025.
Net income
Net income
Diluted EPS
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
KIRA summarises the numbers
Free cash flow was β$29.9M in fiscal 2025, β38.7% of revenue.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
In the last 12 months, insiders bought $0.2M and sold $2.9M of shares on the open market.
Bought, 12 months
$0.2M
1 insider
Sold, 12 months
$2.9M
6 insiders
Of sales under plans
76%
$2.2M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Alison BauerleinChief Operating Officer | Sold plan | 25,260 | $8.85 | $0.2M | Form 4 |
| Oct 2, 2026 | James RodbergChief Financial Officer | Sold plan | 7,208 | $8.85 | $0.1M | Form 4 |
| Oct 2, 2026 | Brenton TaylorEVP, Operations & R&D | Sold plan | 2,988 | $8.85 | $0.0M | Form 4 |
| Oct 1, 2026 | David BadawiChief Technology Officer, Director | Sold plan | 7,797 | $9.05 | $0.1M | Form 4 |
| Oct 1, 2026 | Paul BadawiPresident and CEO, Director, 10% owner | Sold plan | 29,653 | $9.05 | $0.3M | Form 4 |
| Jul 6, 2026 | Jeremy B. HaydenChief Legal Officer | Sold plan | 12,733 | $5.51 | $0.1M | Form 4 |
| Jul 6, 2026 | David BadawiChief Technology Officer, Director | Sold plan | 7,418 | $5.51 | $0.0M | Form 4 |
| Jul 2, 2026 | James RodbergChief Financial Officer | Sold plan | 6,902 | $5.36 | $0.0M | Form 4 |
| Jul 2, 2026 | Alison BauerleinChief Operating Officer | Sold plan | 24,184 | $5.36 | $0.1M | Form 4 |
| Jul 1, 2026 | Paul BadawiPresident and CEO, Director, 10% owner | Sold plan | 28,684 | $5.42 | $0.2M | Form 4 |
| Jul 1, 2026 | Brenton TaylorEVP, Operations & R&D | Sold plan | 2,829 | $5.42 | $0.0M | Form 4 |
| Jun 10, 2026 | Staffan EncrantzDirector, 10% owner | Bought | 14,100 | $4.88 | $0.1M | Form 4 |
| May 18, 2026 | Alison BauerleinChief Operating Officer | Sold plan | 12,728 | $5.12 | $0.1M | Form 4 |
| Apr 6, 2026 | Jeremy B. HaydenChief Legal Officer | Sold plan | 13,761 | $3.55 | $0.0M | Form 4 |
| Apr 6, 2026 | James RodbergChief Financial Officer | Sold plan | 7,231 | $3.55 | $0.0M | Form 4 |
| Apr 2, 2026 | David BadawiChief Technology Officer, Director | Sold plan | 8,168 | $3.48 | $0.0M | Form 4 |
| Apr 2, 2026 | Alison BauerleinChief Operating Officer | Sold plan | 25,874 | $3.48 | $0.1M | Form 4 |
| Apr 1, 2026 | Brenton TaylorEVP, Operations & R&D | Sold plan | 2,869 | $3.70 | $0.0M | Form 4 |
| Apr 1, 2026 | Paul BadawiPresident and CEO, Director, 10% owner | Sold plan | 29,244 | $3.70 | $0.1M | Form 4 |
| Jan 16, 2026 | Paul BadawiPresident and CEO, Director, 10% owner | Sold plan | 22,362 | $6.62 | $0.1M | Form 4 |
| Jan 16, 2026 | Jeremy B. HaydenChief Legal Officer | Sold plan | 6,308 | $6.62 | $0.0M | Form 4 |
| Jan 16, 2026 | David BadawiChief Technology Officer, Director | Sold plan | 4,836 | $6.62 | $0.0M | Form 4 |
| Jan 16, 2026 | James RodbergChief Financial Officer | Sold plan | 2,616 | $6.62 | $0.0M | Form 4 |
| Jan 6, 2026 | Jeremy B. HaydenChief Legal Officer | Sold plan | 1,785 | $7.48 | $0.0M | Form 4 |
| Jan 6, 2026 | Paul BadawiPresident and CEO, Director, 10% owner | Sold | 11,870 | $7.48 | $0.1M | Form 4 |
| Jan 6, 2026 | James RodbergChief Financial Officer | Sold | 594 | $7.48 | $0.0M | Form 4 |
| Jan 6, 2026 | David BadawiChief Technology Officer, Director | Sold | 3,695 | $7.48 | $0.0M | Form 4 |
| Jan 6, 2026 | Brenton TaylorEVP, Operations & R&D | Sold | 619 | $7.48 | $0.0M | Form 4 |
| Jan 6, 2026 | Alison BauerleinChief Operating Officer | Sold | 9,647 | $7.48 | $0.1M | Form 4 |
| Jan 5, 2026 | James RodbergChief Financial Officer | Sold | 4,405 | $7.82 | $0.0M | Form 4 |
| Jan 5, 2026 | Jeremy B. HaydenChief Legal Officer | Sold plan | 9,385 | $7.82 | $0.1M | Form 4 |
| Jan 5, 2026 | David BadawiChief Technology Officer, Director | Sold | 3,051 | $7.82 | $0.0M | Form 4 |
| Jan 5, 2026 | Alison BauerleinChief Operating Officer | Sold | 10,896 | $7.82 | $0.1M | Form 4 |
| Jan 2, 2026 | Paul BadawiPresident and CEO, Director, 10% owner | Sold | 25,356 | $7.43 | $0.2M | Form 4 |
| Jan 2, 2026 | David BadawiChief Technology Officer, Director | Sold | 2,914 | $7.43 | $0.0M | Form 4 |
| Dec 16, 2025 | Staffan EncrantzDirector, 10% owner | Bought | 13,958 | $8.31 | $0.1M | Form 4 |
| Dec 2, 2025 | James RodbergChief Financial Officer | Sold | 2,518 | $8.25 | $0.0M | Form 4 |
| Nov 25, 2025 | Jeremy B. HaydenChief Legal Officer | Sold plan | 44,850 | $8.08 | $0.4M | Form 4 |
| Nov 17, 2025 | Brenton TaylorEVP, Operations & R&D | Sold | 14,418 | $7.06 | $0.1M | Form 4 |
| Nov 12, 2025 | Jeremy B. HaydenChief Legal Officer | Sold plan | 3,150 | $8.01 | $0.0M | Form 4 |
| Oct 6, 2025 | Brenton TaylorEVP, Operations & R&D | Sold | 591 | $3.37 | $0.0M | Form 4 |
| Oct 3, 2025 | Jeremy B. HaydenChief Legal Officer | Sold | 9,731 | $3.27 | $0.0M | Form 4 |
| Oct 3, 2025 | David BadawiChief Technology Officer, Director | Sold | 6,033 | $3.27 | $0.0M | Form 4 |
| Oct 2, 2025 | Alison BauerleinChief Financial Officer | Sold | 19,948 | $3.30 | $0.1M | Form 4 |
| Oct 1, 2025 | Paul BadawiPresident and CEO, Director, 10% owner | Sold | 24,441 | $3.34 | $0.1M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Sight Sciences, Inc. can carry it.
KIRA summarises the numbers
Sight Sciences, Inc. has $49.6M more cash than debt.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $261M | $185M | $138M | $120M | $92.0M |
| Debt incl. finance leases | $35.0M | $35.0M | $35.0M | $40.0M | $42.4M |
| Debt / equity | 0.2x | 0.2x | 0.3x | 0.5x | 0.7x |
| Interest coverage | β11.8x | β18.8x | β10.6x | β10.8x | β7.2x |
| Current ratio | 20.5x | 11.8x | 13.3x | 9.0x | 10.2x |
| Quick ratio | 20.3x | 11.4x | 12.7x | 8.6x | 9.5x |
| Total assets | $280M | $213M | $167M | $143M | $115M |
| Total liabilities | $48.1M | $53.0M | $46.4M | $55.3M | $51.4M |
| Shareholders' equity | $232M | $160M | $120M | $87.5M | $63.9M |
| Net debt (β = net cash) | β$226M | β$150M | β$103M | β$80.4M | β$49.6M |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
KIRA summarises the numbers
Its return on capital was β204.1%: every 100 invested in the business earned about β204 in a year.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
Sight Sciences, Inc. passes 5 of 9 financial health tests (Piotroski F-score).
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 3 / 9 | 5 / 9 | 3 / 9 | 5 / 9 |
| Accruals ratio | β3.5% | β5.9% | β4.2% | β4.4% | β18.8% | β6.8% |
| Altman Z'' | β3.58 | 8.22 | 2.77 | 0.57 | β2.91 | β5.95 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $27.6M | $49.0M | $71.3M | $81.1M | $79.9M | $77.4M |
| Gross profit | $18.4M | $40.3M | $59.0M | $69.2M | $68.3M | $66.7M |
| Research and development | $8.9M | $15.6M | $22.9M | $17.6M | $18.0M | $14.6M |
| Operating income | β$32.2M | β$51.5M | β$84.0M | β$57.3M | β$50.5M | β$37.1M |
| Interest expense | $2.4M | $4.4M | $4.5M | $5.4M | $4.7M | $5.1M |
| Pretax income | β$34.6M | β$62.8M | β$86.2M | β$55.4M | β$51.3M | β$38.4M |
| Income tax | $0.1M | $0.2M | $0.0M | $0.1M | $0.2M | $0.0M |
| Net income | β$34.7M | β$63.0M | β$86.2M | β$55.5M | β$51.5M | β$38.4M |
| Diluted EPS | β$3.71 | β$2.36 | β$1.80 | β$1.14 | β$1.03 | β$0.74 |
| Diluted shares | 0.01B | 0.03B | 0.05B | 0.05B | 0.05B | 0.05B |
| Cash flow | ||||||
| Cash from operations | β$32.2M | β$52.5M | β$76.0M | β$47.2M | β$22.4M | β$29.7M |
| Capital expenditure | $1.0M | $0.8M | $1.0M | $0.8M | $0.4M | $0.2M |
| Free cash flow | β$33.1M | β$53.4M | β$76.9M | β$48.0M | β$22.7M | β$29.9M |
| Depreciation and amortization | $0.6M | $0.6M | $0.7M | $0.6M | $0.7M | $0.5M |
| Stock-based compensation | $0.5M | $5.1M | $13.0M | $14.6M | $17.1M | $13.1M |
| Balance sheet | ||||||
| Cash and short-term investments | $61.5M | $261M | $185M | $138M | $120M | $92.0M |
| Total debt | $32.0M | $35.0M | $35.0M | $35.0M | $40.0M | $42.4M |
| Current assets | $70.6M | $277M | $210M | $163M | $140M | $113M |
| Current liabilities | $9.3M | $13.5M | $17.8M | $12.3M | $15.5M | $11.0M |
| Inventory | $2.6M | $3.5M | $6.1M | $7.8M | $6.3M | $7.8M |
| Property and equipment, net | $1.3M | $1.5M | $1.6M | $1.6M | $1.6M | $1.6M |
| Total assets | $72.8M | $280M | $213M | $167M | $143M | $115M |
| Total liabilities | $44.3M | $48.1M | $53.0M | $46.4M | $55.3M | $51.4M |
| Preferred stock | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$88.8M | $232M | $160M | $120M | $87.5M | $63.9M |
| Margins | ||||||
| Gross margin | 66.7% | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| Operating margin | β116.5% | β105.2% | β117.7% | β70.7% | β63.3% | β48.0% |
| EBITDA margin | β114.5% | β103.9% | β116.7% | β69.9% | β62.4% | β47.3% |
| Net margin | β125.5% | β128.6% | β120.9% | β68.5% | β64.5% | β49.7% |
| FCF margin | β119.9% | β109.0% | β107.9% | β59.2% | β28.5% | β38.7% |
| Returns | ||||||
| Return on capital | β | β633.5% | β658.2% | β264.8% | β557.1% | β204.1% |
| Return on capital employed | β50.7% | β19.3% | β43.0% | β37.1% | β39.7% | β35.6% |
| Return on equity | β | β87.9% | β44.0% | β39.6% | β49.6% | β50.7% |
| Return on assets | β47.7% | β35.7% | β35.0% | β29.3% | β33.3% | β29.8% |
| Return on tangible equity | β | β27.1% | β53.9% | β46.2% | β58.8% | β60.1% |
| Growth | ||||||
| Revenue growth | β | 77.1% | 45.7% | 13.6% | β1.5% | β3.1% |
| Share count change | β | 185.7% | 79.0% | 1.6% | 3.1% | 4.0% |
| Financial health | ||||||
| Debt / equity | β | 0.2x | 0.2x | 0.3x | 0.5x | 0.7x |
| Interest coverage | β13.4x | β11.8x | β18.8x | β10.6x | β10.8x | β7.2x |
| Current ratio | 7.6x | 20.5x | 11.8x | 13.3x | 9.0x | 10.2x |
| Quick ratio | 7.3x | 20.3x | 11.4x | 12.7x | 8.6x | 9.5x |
| Capital allocation | ||||||
| Capex / revenue | 3.4% | 1.7% | 1.4% | 1.0% | 0.5% | 0.3% |
| Stock comp / revenue | 1.8% | 10.4% | 18.2% | 18.0% | 21.4% | 16.9% |
| Quality scores | ||||||
| Piotroski F-score | β | 5.0 | 3.0 | 5.0 | 3.0 | 5.0 |
| Altman Z'' | β3.6 | 8.2 | 2.8 | 0.6 | β2.9 | β5.9 |
| Accruals ratio | β3.5% | β5.9% | β4.2% | β4.4% | β18.8% | β6.8% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001531177). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
